CAD and neoplasm: Additionally, the combination of MSCs and CAR T-cell-based therapy increased the overall numbers of human CAR T cells in experimental animals and enhanced their capacity for secretion of inflammatory and tumorotoxic cytokines, indicating that CAd-infected MSCs managed to improve activation and persistence of CAR T cells in the tumor microenvironment [26].